Brazil Semaglutide Race Opens as Anvisa Clears Five Pens Brazil Business Key Facts Patent expiry Novo Nordisks semaglutide patent expired in March 2026, ending exclusivity for Ozempic and Wegovy in Brazil
This is particularly relevant for people who were already well-controlled on antihypertensives before starting semaglutide, since weight loss itself tends to lower blood pressure, potentially creating an additive effect
Anthropometric changes Some studies compared the liraglutide 1.8 mg/day vs
Not approved or evaluated by the FDA for human use. (Regentherapy) Thus any use in humansoutside a formal clinical trialis off-label and subject to regulatory risks (depending on jurisdiction)
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
As a result, current clinical guidelines for T2DM, kidney disease, and cardiovascular care strongly recommend the use of GLP-1RAs and SGLT2is in patients with T2DM who have, or are at high risk for, atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD)